Open Access

Dexmedetomidine inhibits Tetrodotoxin-resistant Nav1.8 sodium channel activity through Gi/o-dependent pathway in rat dorsal root ganglion neurons

  • Xi-Yao Gu1,
  • Ben-Long Liu1,
  • Kai-Kai Zang1,
  • Liu Yang1,
  • Hua Xu2,
  • Hai-Li Pan3,
  • Zhi-Qi Zhao1 and
  • Yu-Qiu Zhang1Email author
Contributed equally
Molecular Brain20158:15

https://doi.org/10.1186/s13041-015-0105-2

Received: 30 November 2014

Accepted: 18 February 2015

Published: 3 March 2015

Abstract

Background

Systemically administered dexmedetomidine (DEX), a selective α2 adrenergic receptor (α2-AR) agonists, produces analgesia and sedation. Peripherally restricted α2-AR antagonist could block the analgesic effect of systemic DEX on neuropathic pain, with no effect on sedation, indicating peripheral analgesic effect of DEX. Tetrodotoxin-resistant (TTX-R) sodium channel Nav1.8 play important roles in the conduction of nociceptive sensation. Both α2-AR and Nav1.8 are found in small nociceptive DRG neurons. We, therefore, investigated the effects of DEX on the Nav1.8 currents in acutely dissociated small-diameter DRG neurons.

Results

Whole-cell patch-clamp recordings demonstrated that DEX concentration-dependently suppressed TTX-R Nav1.8 currents in small-diameter lumbar DRG neurons. DEX also shifted the steady-state inactivation curves of Nav1.8 in a hyperpolarizing direction and increased the threshold of action potential and decrease electrical and chemical stimuli-evoked firings in small-diameter DRG neurons. The α2-AR antagonist yohimbine or α2A-AR antagonist BRL44408 but not α2B-AR antagonist imiloxan blocked the inhibition of Nav1.8 currents by DEX. Immunohistochemistry results showed that Nav1.8 was predominantly expressed in peripherin-positive small-diameter DRG neurons, and some of them were α2A-AR-positive ones. Our electrophysiological recordings also demonstrated that DEX-induced inhibition of Nav1.8 currents was prevented by intracellular application of G-protein inhibitor GDPβ-s or Gi/o proteins inhibitor pertussis toxin (PTX), and bath application of adenylate cyclase (AC) activator forskolin or membrane-permeable cAMP analogue 8-Bromo-cAMP (8-Br-cAMP). PKA inhibitor Rp-cAMP could mimic DEX-induced inhibition of Nav1.8 currents.

Conclusions

We established a functional link between α2-AR and Nav1.8 in primary sensory neurons utilizing the Gi/o/AC/cAMP/PKA pathway, which probably mediating peripheral analgesia of DEX.

Keywords

α2-adrenoceptor Dexmedetomidine Dorsal root ganglion Pain Tetrodotoxin-resistant (TTX-R) sodium channel Nav1.8 Whole-cell recording

Background

Dexmedetomidine (DEX), a potent and highly selective agonist of the alpha 2 adrenergic receptors (α2-ARs) with more favorable pharmacokinetic properties than clonidine (another commonly used α2-AR agonist) is approved for the adult intensive care unit use as sedative infusion by the US Food and Drug Administration in 1999. Three α2-ARs (α2A-, α2B- and α2C-ARs) have been cloned, and all of which are coupled to inhibitory G proteins [1] and play an important role in the control of pain. The α2-ARs have a diffuse distribution in the nervous system, including in primary afferents, spinal dorsal horn and brain stem [2-5]. Systemically administered α2-AR agonists produce anti-nociceptive effects in humans and animals, suggesting that the α2-AR may be involved in anti-nociception at the supraspinal, spinal and peripheral levels [6-9]. Our previous study showed that intrathecal DEX significantly suppressed monoarthritis-induced thermal hyperalgesia and glial activation in spinal level [10]. However, intrathecal or intracerebroventricular administration of DEX produces dose-dependent sedation [11]. Peripherally restricted α2-AR antagonist could block the analgesic effect of systemic DEX on neuropathic pain, with no effect on sedation, indicating peripheral analgesic effect of DEX [7].

Evidence has emerged that the effects on ion channels may be an important mechanism underlying DEX-induced peripheral anti-nociception [12,13]. Previous studies have revealed that changes in function of voltage-gate sodium channels in nociceptive primary sensory neurons participate in the development of peripheral hyperexcitability that occurs in neuropathic and inflammatory pain conditions [14,15]. Among them, the tetrodotoxin-resistant (TTX-R) sodium channel Nav1.8 primarily expressed by small- and medium-sized dorsal root ganglion (DRG) neurons [16,17], substantially contributes to the upstroke of action potential in these neurons [18]. Nav1.8-null mice displayed a pronounced increase in threshold to noxious mechanical stimuli and a slight decrease in nociceptive thermoreception as well as delayed development of inflammatory hyperalgesia [19]. Likewise, functional knockdown of Nav1.8 in rats reduces hyperalgesia and allodynia in neuropathic pain and inflammatory pain models [14,20,21]. Several G-protein-coupled receptors (GPCRs)-mediated second-messenger cascades including PKA, PKC and MAPKs have been shown to regulate Nav1.8 sodium channels [14,22]. In the present study, we investigated whether the peripheral DEX-induced analgesia might in part arise from the suppressed activation of TTX-R sodium channel Nav1.8 currents via binding to its GPCR α2-ARs in small-diameter DRG neurons.

Results

Recording of Nav1.8 currents in DRG neurons

Double immunofluorescence revealed that Nav1.8 was predominantly expressed in peripherin-positive small-diameter DRG neurons (Figure 1A). In the present study, all recordings were performed in small-diameter (<25 μm) DRG neurons. With existence of TTX (500 nM) in external solution, TTX-resistant (TTX-R) sodium currents were recorded in most (170 out of 223) of the small-diameter DRG neurons. As our previous reported, the membrane potential was held at −60 mV to inhibit Nav1.9 currents, leaving the Nav1.8 currents intact [22]. The family of Nav1.8 currents was generated with a voltage-clamp protocol (holding at -60 mV, depolarizing steps from -55 mV to +40 mV, 50 ms, 5 mV increment, Figure 1B). According to the current–voltage relationship (Figure 1C), we selected -15 mV to elicit Nav1.8 currents in most of the recordings (Figure 1D). The peak amplitude of Nav1.8 currents was stable during the recordings.
Figure 1

Isolation of TTX-resistant Na v 1.8 currents in small-diameter DRG neurons. (A) Double immunofluorescence reveals the expression of Nav1.8 in peripherin-positive small-diameter DRG neurons. (B) Representative I-V curve family of currents recorded in the presence of 500 nM TTX. Cells were depolarized to a variety of potentials (−55 mV to +40 mV) from a holding potential of -60 mV, to elicit Nav1.8 currents. (C) I-V curve of Nav1.8 currents shown in (B). (D) Representative traces of Nav1.8 currents elicited by a single pulse of −15 mV.

Effects of DEX on Nav1.8 currents in small DRG neurons

Application of DEX in different doses (0.03, 0.1, 0.3, 1, 3 and 30 μM) dose-dependently reduced the peak amplitude of Nav1.8 currents in small DRG neurons within 1 min and washed out within 5 min (Figure 2A and B). One-way ANOVA analysis revealed a significant effect of DEX treatment (F6,66 = 23.885, p < 0.001). The ED50 was calculated to be 0.92 μM (95% CI: 0.77–1.68). The maximal inhibitory effect (36.51 ± 5.39%) was induced by 3 μM DEX. A higher concentration of DEX (30 μM) failed to induce more powerful inhibition (34.56 ± 2.7%), indicating a “ceiling effect” at a concentration of 3 μM (Figure 2C).
Figure 2

DEX dose-dependently inhibits Na v 1.8 currents. (A, B) Typical traces illustrating the Nav1.8 currents in small-diameter DRG neurons recorded pre- (control) and post- (DEX) perfusion of DEX and wash out. (C) Dose-effect curve of DEX-induced inhibition of Nav1.8 currents. The currents were measured after a 1-min application of different concentrations of DEX.

The effects of DEX on the activation and inactivation properties of Nav1.8 currents were studied using the appropriate voltage protocols. As described above, a voltage-clamp protocol consisted of 50 ms depolarizing steps from -55 mV to +40 mV with 5 mV increment was used to determine the activation of Nav1.8 channels. No shift in the voltage-dependent activation curve was observed in DEX-treated group compared with control one (Figure 3A). The half-maximal activation potential (V1/2 activation) was −27.30 ± 2.13 mV (n = 7) and −28.17 mV ± 0.73 mV (n = 7) in the absence and presence of 3 μM DEX, respectively. Steady-state inactivation of Nav1.8 channel was determined at a series of membrane potentials from −60 mV to −20 mV with 5 mV increment for 500 ms and a following test potential of −15 mV. DEX caused a left shift toward the hyperpolarizing potential of the steady-state inactivation curve (Figure 3B). The V1/2 inactivation was −40.49 ± 2.49 mV (n = 9) of the control and −45.39 ± 2.65 mV (n = 9) of DEX treatment, respectively.
Figure 3

Effect of DEX on the steady-state activation and inactivation curves of Na v 1.8. (A) DEX (3 μM) did not shift voltage-dependent activation curve. (B) DEX (3 μM) shifted the steady-state inactivation curve in a hyperpolarizing direction.

DEX reduced Nav1.8 currents via α2A-AR

DEX was a selective alpha 2 adrenergic receptor (α2-AR) agonist. To address whether the attenuation of Nav1.8 currents induced by DEX application was mediated by α2-ARs, the effect of yohimbine, an α2-ARs antagonist, on inhibitory effects of DEX on Nav1.8 currents was examined. Like previous report [12], yohimbine (30 μM) per se inhibited Nav1.8 currents (Figure 4A). Pretreatment of DRG neurons with 3 μM yohimbine, a concentration to antagonize DEX-induced membrane hyperpolarization mediated by α2-ARs in rat hypothalamic neurons [23], DEX-induced suppression of the Nav1.8 currents was significantly blocked (Figure 4B and C). The peak densities of Nav1.8 currents in yohimbine (3 μM) plus DEX (3 μM)-treated group was significantly greater than that in DEX-treated group (One-way ANOVA, F3, 26 = 5.451, p < 0.01). Moreover, we examined the effect of BRL44408 (a preferential α2A-AR antagonist) on DEX-induced inhibition of Nav1.8 currents. Pre-incubation of BRL44408 (1 μM) alone did not affect the peak densities of Nav1.8 currents, but significantly blocked DEX-induced suppression of Nav1.8 currents (Figure 4D and F). Given that BRL44408 may also be able to block α2B-AR at a higher dose, we further examined the effect of α2B-AR antagonist imiloxan on DEX-induced inhibition of Nav1.8 currents. Neither basal Nav1.8 currents nor DEX-induced suppression was influenced by incubation of imiloxan (3 μM) (Figure 4E and F). These data indicated that DEX modulated Nav1.8 currents mainly through α2A-AR. Also, the colocalization of Nav1.8 with α2A-AR in DRG small-diameter neurons provided a cellular basis for the involvement of α2A-AR in the DEX modulating Nav1.8 currents (Figure 4G).
Figure 4

α2-AR mediates inhibition of DEX on Na v 1.8 currents. (A) The effects of different doses of yohimbine (α2-AR antagonist) on Nav1.8 currents. (B, C) pre-incubation of yohimbine (3 μM) for 30 min blocked the inhibitory effect of DEX (3 μM) on Nav1.8 currents. *p < 0.05. (D-F) DEX-induced inhibition of Nav1.8 currents were completely blocked by pre-incubation of α2A-AR antagonist BRL44408 (1 μM) but not by α2B-AR antagonist imiloxan (3 μM). (G) Immunofluorescence micrographs of two adjacent sections from a DRG (L5) after incubation with α2A-AR antibody and Nav1.8 antibody. Arrowhead indicates coexistence between α2A-AR and Nav1.8 in the same neurons.

Gi/o-proteins participate in DEX-induced Nav1.8 currents inhibition

Given α2-ARs act through G-proteins, we examined the effect of GDPβ-s, a G protein inhibitor, on DEX-induced rapid suppression of Nav1.8 currents in small DRG neurons. Inclusion in pipette solution of GDPβ-s (1 mM) did not impair Nav1.8 activation. On the other hand, the inhibition of Nav1.8 currents by DEX was completely abolished (Figure 5A and C) (One-way ANOVA, F3,38 = 12.757, p < 0.01).
Figure 5

Involvement of G i/o proteins/AC/cAMP/PKA pathway in DEX-induced inhibition of Na v 1.8 currents. (A-C) Loading neurons with 1 mM GDPβ-s or PTX completely abolished the inhibitory effect of DEX on Nav1.8 currents. *p < 0.05. (D, E) Pre-incubation PKA inhibitor Rp-cAMP (50 μM) inhibited Nav1.8 currents. Co-application of DEX did not cause a further reduction of the current amplitudes. *p < 0.05. (F, G) Pre-incubation cAMP analogues 8-Br-cAMP (500 μM) prevented DEX-induced inhibition of Nav1.8 currents. (H, I) Pre-incubation AC activator forskolin (0.1 μM) prevented DEX-induced inhibition of Nav1.8 currents.

α2A-ARs are generally known to coupled to the inhibitory Gi proteins [24] through which they inhibit adenylate cyclase (AC) activity. Therefore, we examined whether DEX-induced inhibition of Nav1.8 currents occurs via Gi proteins. As shown in Figures 5B and C, pertussis toxin (PTX, 1 μg/ml), an irreversible inhibitor of Gi/o-proteins, significantly prevented the Nav1.8 currents amplitude change induced by DEX (One-way ANOVA, F3,30 = 15.765, p < 0.01). Inclusion in pipette solution of PTX (1 μg/ml) did not change Nav1.8 currents amplitude (Figure 5B and C).

Because Gi proteins inhibit the catalytic activity of AC, which catalyzes cAMP production, the Gi-mediated suppression of Nav1.8 currents can be the consequence of decreased levels of intracellular cAMP and a concomitant reduction in PKA-dependent phosphorylation of Nav1.8. Here, we used Rp-cAMP, 8-Br-cAMP and forskolin to examine the effects of AC-cAMP-PKA pathway on the Nav1.8 currents. Incubate with PKA inhibitor Rp-cAMP (50 μM) for 5 min, Nav1.8 currents were significantly suppressed. Co-application of 3 μM DEX did not cause a further reduction of the currents amplitudes (Figure 5D and E). Moreover, 5-min pretreatment of DRG neurons with 8-Br-cAMP (500 μM) a membrane-permeable cAMP analogues, or forskolin (0.1 μM), a AC activator, caused slight increase in Nav1.8 currents amplitude (Figure 5 F-I). Although the increase did not reach statistical significance, it totally removed the inhibitory effect of DEX on Nav1.8 currents (Figure 5G and I).

Effect of dexmedetomidine on excitability of DRG neurons

Nav1.8 is the main contributor to the upstroke of action potentials in small-diameter DRG neurons [18]. Thus, modulation of this channel by DEX should influence the excitability of DRG neurons. We applied 10 ms step depolarizing currents pulse to evoke action potentials. In 13 of 23 neurons tested, DEX 3 μM significantly increase the injected currents threshold to evoke action potentials from 37.5 ± 4.97 pA to 61.88 ± 5.78 pA before and after exposure to DEX respectively (paired t-test, p < 0.01) (Figure 6A and B). Moreover, by injection of maximum currents pulse (500 ms, 200 pA), action potential firing frequencies of DRG neurons were significantly decreased by DEX treatment (Figure 6C and E). DEX-induced inhibitory effect on action potential firing can be mimicked by selective α2A-AR agonist guanfacine (30 μM) (Figure 6D and E). Similarly, 0.5 μM capsaicin-induced action potentials were also significantly blocked by DEX (Figure 6F and G).
Figure 6

Effect of DEX on the action potential threshold and firing rate of DRG neurons. (A) In current clamp model, depolarizing current pulse required to evoke an action potential in a DRG neuron before and after application of DEX (a = 25 pA, b = 30 pA, c = 40 pA, d = 45 pA). (B) DEX (3 μM) reduced the amount of currents required to evoke action potential. (C, D) Firing response of DRG neurons to a 200 pA depolarizing current pulse (500 ms) before and after application of DEX (C) and selective α2A-AR agonist guanfacine (D). (E) Summary data indicate the inhibitory effects of DEX and guanfacine on firing rate in DRG neurons. (F, G) Current clamp recording showing suppression of capsaicin-induced action potential firing by DEX (3 μM). *p < 0.05; **p < 0.01.

Discussion

In this study, we demonstrated that selective α2-AR agonist dexmedetomidine (DEX) reduced Nav1.8 currents in small-diameter acutely dissociated DRG neurons. We also showed that DEX decreased excitability of small sensory neurons by increasing the activation threshold and decreasing the action potential firing. This inhibition of Nav1.8 currents was completely blocked by the selective α2A-AR antagonist, suggesting that α2A-AR might be directly involved in DEX-induced changes in Nav1.8 activity. We also found that the PTX-sensitive Gi/o proteins/AC/cAMP/PKA signaling cascade is primarily responsible for the activation of Nav1.8 currents in response to DEX in DRG neurons. These results suggest a peripheral mechanism of DEX analgesia.

TTX-R sodium channel primarily expresses in DRG nociceptors [25,26]. In the two distinct TTX-R sodium channel isoforms Nav1.8 and Nav1.9, Nav1.8 likely mediates the majority of TTX-R currents. Accumulating evidence points up that TTX-R sodium channel plays an important role in peripheral pain processing [27]. Nociceptive signals evoke a dynamic change of TTX-R sodium channel, for example, chronic compression (CCD) of the DRG [15,28] or local inflammation of the DRG by the application of zymosan [29] and subcutaneous injection of carrageenan [30] or complete Freund’s adjuvant (CFA) [31] produces an increase in TTX-R sodium currents in small DRG neurons. Either the physiological or pathological pain was alleviated in the Nav1.8-null mice or Nav1.8 knockdown rats [14,27,32,33]. Peripheral inflammation or nerve injury has been shown to upregulate Nav1.8 expression in nociceptive DRG neurons [34,35]. Blockade of Nav1.8 sodium channel by A-803467, a potent and selective Nav1.8 sodium channel blocker, could inhibit nerve injury-induced mechanical allodynia and inflammation-induced thermal hyperalgesia [36].

Given that both α2-AR and Nav1.8 are found in small nociceptive DRG neurons [4,5,37], and α2A-AR and Nav1.8 co-localized in the same small DRG neurons, we propose that stimulation of α2-AR in sensory neurons may lead to an attenuation of the painful symptoms of hypersensitivity via the inhibition of Nav1.8 channel activity. Consistently, application of DEX concentration-dependently decreased the current density of Nav1.8 in small DRG neurons and shifted the voltage-dependence of steady-state inactivation curve for Nav1.8 in the hyperpolarizing direction, which could result in a lower threshold for Na+ channel inactivation. DEX also increased the threshold of action potential and decreased firing rate in small DRG neurons. Despite of the previous reports that yohimbine did not alter DEX-induced inhibition of TTX-R Na+ currents in small DRG neurons [12] and voltage-gated Na+ currents in NG108-15 cells [13], the present study showed that 3 μM yohimbine, a concentration to antagonize DEX-induced membrane hyperpolarization mediated by α2-ARs in rat hypothalamic neurons [23], completed blocked DEX-induced suppression of the Nav1.8 currents, suggesting an involvement of α2-ARs in DEX effect. Considering the affinity of yohimbine for α1-ARs, serotonin and dopamine receptors [38], inhibition of high dose yohimbine per se on Nav1.8 currents may relate to the interaction of yohimbine with these receptors.

Although three subtypes of the α2-ARs mRNAs were expressed in the rat DRGs [5,39,40], α2B-AR mRNA was only found in small numbers of neuron profiles [5,41], and following peripheral nerve injury, α2A-AR and α2C-AR mRNA levels increased and decreased, respectively [5,40]. Also, the immunohistochemical analysis showed that α2A-AR and α2C-AR proteins in DRG neurons was respectively increased and decreased after chronic constriction injury of sciatic nerve, whereas no α2B-AR neurons were detected in either normal or nerve injury DRG [42]. Moreover, α2A-AR rather than α2C-AR in the superficial layers of spinal dorsal horn was observed in the terminals of capsaicin-sensitive and substance P-containing primary afferent fibers [2]. Degeneration of TRPV1 afferent terminals, the level of α2A-AR, but not α2C-AR, was largely reduced in primary afferent terminals [43]. Our present study further showed co-localization of α2A-AR- and Nav1.8-like immunoreactivity in small DRG neurons. DEX-induced inhibition of Nav1.8 currents was prevented by pretreatment of BRL44408, a preferential α2A-AR antagonist, but not of imiloxan, a α2B-AR antagonist. In addition to Nav1.8, other cation channels, for example, TRPM8 may also participate in α2A-AR-mediated nociceptive inhibition. Stimulation of α2A-AR inhibited TRPM8 in DRG neurons [44]. Taken together, these findings suggest that the α2A-AR subtype represents the most likely candidate in DRG neurons to be involved in the modulation of nociceptive information.

Our data strongly suggest that DEX inhibits Nav1.8 currents in a Gi/o proteins/AC/cAMP/PKA signaling-dependent manner in small DRG neurons. Specifically, we showed that preventing Gi/o recruitment by PTX treatment blocked DEX-induced inhibition of Nav1.8 current density, and PKA inhibitor mimicked the effect of DEX through the receptor. In support of this, it has been also reported that blockade of PKA activity inhibited the baseline Nav1.8 currents in small-diameter nodose ganglion neurons [45]. Consistent with the general notion that stimulation of α2A-AR by DEX brings about Gi-mediated inhibition of AC and reduction of intracellular cAMP levels, AC activator forskolin and cAMP analogues 8Br-cAMP completely reversed DEX-induced inhibition of Nav1.8 currents. These findings suggest that the classical AC/cAMP/PKA signaling pathway resulting from the α2-ARs-mediated activation of PTX-sensitive Gi/o proteins is involved in the regulation of Nav1.8 by DEX.

Conclusions

DEX attenuated TTX-R sodium channel Nav1.8 currents in small-diameter DRG neurons via α2A-AR/Gi/o/AC/cAMP/PKA cascade, which probably constitutes a mechanism of peripheral DEX analgesia.

Materials and methods

Animals

Male adult (100–150 g) Wistar rats were obtained from the Experimental Animal Center, Shanghai Medical College of Fudan University, China. Rats were on a 12 h light/dark cycle with a room temperature of 23 ± 1°C and received food and water ad libitum. All experiments protocols were permitted by the Shanghai Animal Care and Use Committee and followed the policies issued by the International Association for the Study of Pain on the use of laboratory animals. All efforts were made to minimize animal suffering and reduce the numbers of animals used.

Preparation of DRG neurons

Animals were anesthetized with ether and rapidly decapitated. DRGs from L4-L6 lumbar segments were removed and immediately transferred onto DMEM (Gibco, Life Technologies, Grand Island, NY, USA) on ice. The ganglia were minced with fine spring scissors and treated with collagenase (2.67 mg/ml, type IA, Sigma, St. Louis, MO) and trypsin (1 mg/ml, type I, Sigma) in DMEM saturated with CO2/O2 mixed gas at 37°C for 35 min. After wash with standard external solution (in mM, 150 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, adjusted to pH 7.4 with NaOH) three times, the ganglia were then gently triturated using fine fired-polished Pasteur pipettes. The dissociated DRG neurons were plated onto 10-mm diameter coverslips in the 3.5 cm culture dishes and incubated with standard external solution. Each culture dishes contained three or four coverslips and all the experiments were performed within 2–8 h after plating.

Patch-clamp recordings

Whole-cell voltage-clamp and current-clamp recordings of DRG neurons were performed at room temperature (RT, 23 ± 1°C) with an EPC-9 amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany). Stimulation protocols and data acquisition were controlled by the software Pulsefit 8.5 (HEKA Elektronik). All of the recordings were performed in small-diameter (15–25 μm) DRG neurons with resting membrane potentials more negative than −50 mV. Microelectrodes (N51A borosilicate glass, Sutter Instruments) with a resistance of 2–6 MΩ were pulled using a P97 puller (Sutter Instruments). The pipette solution contained (in mM): 140 CsF, 1MgCl2, 1 EGTA, 2.5 Na2ATP, 10 HEPES, pH was adjusted to 7.2 with CsOH. Seals (1–10 GΩ) between the electrode and the cells were established. After the whole-cell configuration was established, the cell membrane capacitance and series resistance were compensated (>80%). Leak currents were subtracted using the online P/4 protocol. The data were sampled at 10 kHz and low-passed at 2 kHz. For Nav1.8 recordings, the external solution contained (in mM): 32 NaCl, 20 TEA-Cl, 105 choline-Cl, 1 MgCl2, 1 CaCl2, 0.1 CdCl2, 10 HEPES, 0.0005 TTX and 10 glucose, adjusted to pH 7.4 with NaOH. For current-clamp recordings, the electrode solution was changed to: 140 KCl, 1 MgCl2, 0.5 CaCl2, 5 EGTA, 10 HEPES, 2.5 Na2ATP, pH was adjusted to 7.2 with KOH. The external solution was changed to: 150 NaCl, 5 KCl, 2.5 CaCl2, 1 MgCl2, 10 HEPES, pH was adjusted to 7.4 with NaOH. DRG neurons were held at −60 mV and Nav1.8 currents were evoked by depolarizing pulses to -15 mV. The activation and inactivation properties of Nav1.8 currents were studied using the appropriate voltage protocols. The voltage-clamp protocol consisted of 50 ms depolarizing steps from -55 mV to +40 mV with 5 mV increment was used to determine the activation of Nav1.8 channels. The Boltzmann function of the form G Na / G Namax = 1 / {1 + exp [(V m1/2 - V m ) / k]} was used to describe the voltage dependence of activation and half activation potential was obtained. Steady-state inactivation of Nav1.8 channel was determined at a series of membrane potentials from −60 mV to −20 mV with 5 mV increment for 500 ms and a following test potential of −15 mV. The steady-state inactivation curve was fitted by the Boltzmann function I Na / I Namax = 1 / (1 + exp [(V - V m1/2 ) / k]), where I Namax is the maximal peak current, V is the prepulse membrane potential.

Drugs

All the drugs were purchased from Sigma (St. Louis, MO, USA). The drugs were dissolved in normal saline as stock solutions. All of the stock solutions were stored at −20°C or −80°C until use. Working concentrations of the drugs were prepared on the day of the experiment from the stock solutions. The drug dosages were selected based on previous reports and our preliminary studies. Dexmedetomidine was applied continuously for 1 min closed to cells via ALA-VM8 perfusion system (ALA Scientific Instruments, Westbury, NY). Yohimbine and BRL44408 were applied to the chamber 30 min before and during the perfusion of dexmedetomidine (DEX). Rp-cAMP, 8-Br-cAMP and forskolin were applied to chamber 5–10 min before and during the DEX perfusion. GDPβ-s and PTX were applied in the pipette internal solution.

Immunohistochemistry

Animals were given an overdose of urethane and were then transcardially perfused with normal saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4, 4°C). DRGs (L4–L6 segments) were removed and postfixed in the same fixative for 2 h at 4°C and then immersed in a 10–30% gradient of sucrose in phosphate buffer for 24–48 h at 4°C for cryoprotection. DRGs were embedded in OCT compound, cut in a cryostat (Leica 1900, Leica) at 7 μm (to study Nav1.8 and α2A-AR coexistence) or 14 μm thickness and mounted onto gelatin coated slides. The sections were placed in a humid chamber and processed for immunohistochemistry. The sections were blocked with 10% donkey serum in 0.01 M PBS (pH 7.4) with 0.3% Triton X-100 for 1 h at RT. For Nav1.8 and peripherin (a small-diameter DRG neuronal marker) double immunofluorescence, the sections were incubated with a mixture of rabbit anti-Nav1.8 (1:1000; Alomone) with mouse anti-peripherin (1:2000; Millipore) overnight at 4°C, followed by a mixture of Alex Flour 488- and Alex Flour 546-conjugated secondary antibodies (1:200; Invitrogen) for 2 h at 4°C. For detecting Nav1.8 and α2A-AR coexistence, two adjacent sections (7 μm) was respectively incubated with rabbit anti-Nav1.8 (1:1000) and rabbit anti-α2A-AR (1:100; Alomone) primary antibodies in PBS with 1% normal donkey serum and 0.3% Triton X-100 overnight at 4°C, followed by incubation within Alex Flour 546- and Alex Flour 488-conjugated secondary antibodies for 2 h at 4°C, respectively. All of the slides were coverslipped with 50% glycerin in 0.01 M PBS and then examined with an Olympus FV1000 confocal laser scanning microscope (Olympus). Images were acquired using FV10-ASW software. The specificities of the immunostaining were verified by observing no immunostaining after omitting the primary antibodies, which resulted in the disappearance of the immunostaining signals. The specificities of the primary antibodies were verified by a preabsorption experiment. Sections were first incubated overnight with a mixture of Nav1.8 or α2A-AR primary antibody and the corresponding blocking peptide (5:1 blocking peptide: primary antibody), followed by incubation with a secondary antibody. The immunostaining signals were abolished after absorption.

Data analysis

The data were presented as means ± standard error of mean (SEM). Statistical comparisons were performed using Student’s t-test, paired t-test and one-way ANOVA followed by post hoc Student-Newman-Keuls test. In all cases, p < 0.05 was considered statistically significant.

Notes

Declarations

Acknowledgements

This work was supported by the National Natural Science Foundation of China (31421091, 31420103903, 31271183 and 81471130, 81200854) and the National Basic Research Program of China (2013CB531900).

Authors’ Affiliations

(1)
Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University
(2)
Department of Anesthesiology, Changhai Hospital, The Second Military Medical University
(3)
Center for Neuropsychiatric Diseases, Institute of Life Science, Nanchang University

References

  1. Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney JW. Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992;42(1):1–5.PubMedGoogle Scholar
  2. Stone LS, Broberger C, Vulchanova L, Wilcox GL, Hökfelt T, Riedl MS, et al. Differential distribution of alpha2A and alpha2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 1998;18(15):5928–37.PubMedGoogle Scholar
  3. Gold MS, Dastmalchi S, Levine JD. Alpha 2-adrenergic receptor subtypes in rat dorsal root and superior cervical ganglion neurons. Pain. 1997;69(1–2):179–90.View ArticlePubMedGoogle Scholar
  4. Medvedeva YV, Kim MS, Schnizler K, Usachev YM. Functional tetrodotoxin-resistant Na(+) channels are expressed presynaptically in rat dorsal root ganglia neurons. Neuroscience. 2009;159(2):559–69.View ArticlePubMedGoogle Scholar
  5. Shi TS, Winzer-Serhan U, Leslie F, Hökfelt T. Distribution and regulation of alpha(2)-adrenoceptors in rat dorsal root ganglia. Pain. 2000;84(2–3):319–30.View ArticlePubMedGoogle Scholar
  6. Aho M, Lehtinen AM, Erkola O, Kallio A, Korttila K. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy. Anesthesiology. 1991;74(6):997–1002.View ArticlePubMedGoogle Scholar
  7. Poree LR, Guo TZ, Kingery WS, Maze M. The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors. Anesth Analg. 1998;87(4):941–8.PubMedGoogle Scholar
  8. Kingery WS, Guo TZ, Davies MF, Limbird L, Maze M. The alpha(2A) adrenoceptor and the sympathetic postganglionic neuron contribute to the development of neuropathic heat hyperalgesia in mice. Pain. 2000;85(3):345–58.View ArticlePubMedGoogle Scholar
  9. Zhang WS, Xu H, Xu B, Sun S, Deng XM, Zhang YQ. Antihyperalgesic effect of systemic dexmedetomidine and gabapentin in a rat model of monoarthritis. Brain Res. 2009;1264:57–66.View ArticlePubMedGoogle Scholar
  10. Xu B, Zhang WS, Yang JL, Lû N, Deng XM, Xu H, et al. Evidence for suppression of spinal glial activation by dexmedetomidine in a rat model of monoarthritis. Clin Exp Pharmacol Physiol. 2010;37(10):e158–66.View ArticlePubMedGoogle Scholar
  11. Buerkle H, Yaksh TL. Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81(2):208–15.View ArticlePubMedGoogle Scholar
  12. Oda A, Iida H, Tanahashi S, Osawa Y, Yamaguchi S, Dohi S. Effects of alpha2-adrenoceptor agonists on tetrodotoxin-resistant Na + channels in rat dorsal root ganglion neurons. Eur J Anaesthesiol. 2007;24(11):934–41.View ArticlePubMedGoogle Scholar
  13. Chen BS, Peng H, Wu SN. Dexmedetomidine, an alpha2-adrenergic agonist, inhibits neuronal delayed-rectifier potassium current and sodium current. Br J Anaesth. 2009;103(2):244–54.View ArticlePubMedGoogle Scholar
  14. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci. 2010;33:325–47.View ArticlePubMedGoogle Scholar
  15. Fan N, Donnelly DF, LaMotte RH. Chronic compression of mouse dorsal root ganglion alters voltage-gated sodium and potassium currents in medium-sized dorsal root ganglion neurons. J Neurophysiol. 2011;106(6):3067–72.View ArticlePubMed CentralPubMedGoogle Scholar
  16. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain. 2007;131(3):243–57.View ArticlePubMed CentralPubMedGoogle Scholar
  17. Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev. 2009;60(1):65–83.View ArticlePubMedGoogle Scholar
  18. Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol. 2001;86(2):629–40.PubMedGoogle Scholar
  19. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2(6):541–8.View ArticlePubMedGoogle Scholar
  20. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain. 2002;95(1–2):143–52.View ArticlePubMedGoogle Scholar
  21. Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, Mould J, et al. muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A. 2006;103(45):17030–5.View ArticlePubMed CentralPubMedGoogle Scholar
  22. Cang CL, Zhang H, Zhang YQ, Zhao ZQ. PKCepsilon-dependent potentiation of TTX-resistant Nav1.8 current by neurokinin-1 receptor activation in rat dorsal root ganglion neurons. Mol Pain. 2009;5:33.View ArticlePubMed CentralPubMedGoogle Scholar
  23. Shirasaka T, Kannan H, Takasaki M. Activation of a G protein-couple inwardly rectifying K+ current and suppression of Ih contribute to dexmedetomidine-induced inhibition of rat hypothalamic paraventricular nucleus neurons. Anesthesiology. 2007;107(4):605–15.View ArticlePubMedGoogle Scholar
  24. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13(6):770–6.View ArticlePubMed CentralPubMedGoogle Scholar
  25. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257–62.View ArticlePubMedGoogle Scholar
  26. Su YY, Ye M, Li L, Liu C, Pan J, Liu WW, et al. KIF5B promotes the forward transport and axonal function of the voltage-gated sodium channel Nav1.8. J Neurosci. 2013;33(45):17884–96.View ArticlePubMedGoogle Scholar
  27. Lampert A, O'Reilly AO, Reeh P, Leffler A. Sodium channelopathies and pain. Pflugers Arch. 2010;460(2):249–63.View ArticlePubMedGoogle Scholar
  28. Fan N, Sikand P, Donnelly DF, Ma C, Lamotte RH. Increased Na + and K+ currents in small mouse dorsal root ganglion neurons after ganglion compression. J Neurophysiol. 2011;106(1):211–8.View ArticlePubMed CentralPubMedGoogle Scholar
  29. Wang JG, Strong JA, Xie W, Zhang JM. Local inflammation in rat dorsal root ganglion alters excitability and ion currents in small-diameter sensory neurons. Anesthesiology. 2007;107(2):322–32.View ArticlePubMed CentralPubMedGoogle Scholar
  30. Tanaka M, Cummins TR, Ishikawa K, Dib-Hajj SD, Black JA, Waxman SG. SNS Na + channel expression increases in dorsal root ganglion neurons in thecarrageenan inflammatory pain model. Neuroreport. 1998;9(6):967–72.View ArticlePubMedGoogle Scholar
  31. Gould 3rd HJ, England JD, Liu ZP, Levinson SR. Rapid sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant. Brain Res. 1998;802(1–2):69–74.View ArticlePubMedGoogle Scholar
  32. Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci. 2002;22(19):8352–6.PubMedGoogle Scholar
  33. Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain. 2006;123(1–2):75–82.View ArticlePubMedGoogle Scholar
  34. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 2004;108(3):237–47.View ArticlePubMedGoogle Scholar
  35. He XH, Zang Y, Chen X, Pang RP, Xu JT, Zhou X, et al. TNF-α contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury. Pain. 2010;151(2):266–79.View ArticlePubMedGoogle Scholar
  36. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A. 2007;104(20):8520–5.View ArticlePubMed CentralPubMedGoogle Scholar
  37. Belkouch M, Dansereau MA, Réaux-Le Goazigo A, Van Steenwinckel J, Beaudet N, Chraibi A, et al. The chemokine CCL2 increases Nav1.8 sodium channel activity in primary sensory neurons through a Gβγ-dependent mechanism. J Neurosci. 2011;31(50):18381–90.View ArticlePubMedGoogle Scholar
  38. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, et al. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse. 2000;35(2):79–95.View ArticlePubMedGoogle Scholar
  39. Nicholas AP, Pieribone V, Hökfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol. 1993;328(4):575–94.View ArticlePubMedGoogle Scholar
  40. Cho HJ, Kim DS, Lee NH, Kim JK, Lee KM, Han KS, et al. Changes in the alpha 2-adrenergic receptor subtypes gene expression in rat dorsal root ganglion in an experimental model of neuropathic pain. Neuroreport. 1997;8(14):3119–22.View ArticlePubMedGoogle Scholar
  41. Chung K, Kim HJ, Na HS, Park MJ, Chung JM. Abnormalities of sympathetic innervation in the area of an injured peripheral nerve in a rat model of neuropathic pain. Neurosci Lett. 1993;162(1–2):85–8.View ArticlePubMedGoogle Scholar
  42. Cheng HJ, Ma KT, Li L, Zhao L, Wang Y, Si JQ. Differential expression of alpha-adrenoceptor subtypes in rat dorsal root ganglion after chronic constriction injury. J Huazhong Univ Sci Technolog Med Sci. 2014;34(3):322–9.View ArticlePubMedGoogle Scholar
  43. Chen SR, Pan HM, Richardson TE, Pan HL. Potentiation of spinal alpha(2)-adrenoceptor analgesia in rats deficient in TRPV1-expressing afferent neurons. Neuropharmacology. 2007;52(8):1624–30.View ArticlePubMed CentralPubMedGoogle Scholar
  44. Bavencoffe A, Gkika D, Kondratskyi A, Beck B, Borowiec AS, Bidaux G, et al. The transient receptor potential channel TRPM8 is inhibited via the alpha 2A adrenoreceptor signaling pathway. J Biol Chem. 2010;285(13):9410–9.View ArticlePubMed CentralPubMedGoogle Scholar
  45. Matsumoto S, Yoshida S, Ikeda M, Tanimoto T, Saiki C, Takeda M, et al. Effect of 8-bromo-cAMP on the tetrodotoxin-resistant sodium (Nav 1.8) current in small-diameter nodose ganglion neurons. Neuropharmacology. 2007;52(3):904–24.View ArticlePubMedGoogle Scholar

Copyright

© Gu et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement